HALTIGRI
Dead / Abandoned — Abandoned — no statement of use filed (as of 18 Oct 2021)
What this means for you
This application is over — abandoned 18 Oct 2021. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90072528
- Mark type
- Stylized text
- Filed
- 24 Jul 2020
- Published for opposition
- 19 Jan 2021
- Abandoned
- 18 Oct 2021
- Attorney of record
- Jared M. Barrett
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of kidney disease; pharmaceutical preparations for the treatment of focal segmental glomerulosclerosis (FSGS); pharmaceutical preparations for the treatment of Immunoglobulin A Nephropathy (IgAN); pharmaceutical preparations for the treatment of Alport Syndrome
Owner
- TRAVERE THERAPEUTICS, INC., SAN DIEGO, CA, US
- TRAVERE THERAPEUTICS, INC., SAN DIEGO, CA, US
- Retrophin, Inc., San Diego, CA, US
Prosecution history
- 18 Oct 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 18 Oct 2021 — ABANDONMENT - NO USE STATEMENT FILED
- 16 Mar 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Jan 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Jan 2021 — PUBLISHED FOR OPPOSITION
- 30 Dec 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Dec 2020 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 14 Dec 2020 — ASSIGNED TO LIE
- 14 Dec 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Dec 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Dec 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Dec 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 Nov 2020 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 16 Nov 2020 — PRIORITY ACTION E-MAILED
- 16 Nov 2020 — PRIORITY ACTION WRITTEN